List of Participants

AARBAKKE, JARLE, Dr. BALANT-GORGIA, A.E., Dr. Institute of Medical Biology Unite Monitoring TMrapeutique University ofTroms0 Departement de Psychiatrie P.O.Box977 Centre Medical Universitaire N-9001 Troms0 CH-1211 Geneva 4 Norway Switzerland

AGREN, HANS, Dr. BARON, J .C., Dr. Department of Psychiatry INSERM Unit 320 University Hospital CYCERON S-751 85 Uppsala Boite Postale 5027 Sweden F-14021 Caen Cedex ALTAMURA, A.C., Dr. France Department of Psychiatry University of Milan BAUMANN, PIERRE, Dr. Via F. Sforza 35 Hopital de Cery 1-20122 Milan Clinique Psychiatrique Italy U niversi taire Canton de Vaud ARESVIK, STaLE, Dr. CH-1008 Prilly Janssen Pharma, Postboks 113 Switzerland N-14150ppegard Norway BECR, PER, Dr. Frederiksborg General Hospital BACCINO, ERIC, Dr. Department of Psychiatry Service Sebileau Dyrehavevej 48 Hopital Augustin Morvan DK-3400 Hillemd 5 avenue Foch Denmark F-29 285 Brest Cedex France BENITEZ, JULIO, Dr. BALANT, Luc P., Dr. Department of Pharmacology Departement de Psychiatrie School of Medicine Case postale 79 University of Extremadura CH-1211 Geneva 8 E-06071 Badajoz Switzerland Spain 318 List of Participants

BERGMAN, THORVALD, Mr. B~TRUP, CLAUS, Dr. Essex Uikemedel AB Pharmaceuticals R&D P.O. Box27190 NOVO Industri AjS S-102 52 Stockholm DK-2880 Bagsverd Sweden Denmark

BERTILSSON, LEIF, Dr. BRATLID, TROND, Dr. Department of Clinical 9010 Asgard Psychiatric Hospital Pharmacology N-9001 Troms0 Huddinge University Hospital Norway S-14186Huddinge Sweden BREKKE-NILSEN, BJ0RN, Dr. 9010 Asgard Psychiatric Hospital BJERKE, CARSTEN, Dr. Psychogeriatric Department N-9001 Troms0 Norway 9010 Asgard Psychiatric Hospital N-9001 Troms0 Norway BRINKMANN, RUDIGER, Dr. Pharma Communications BJERKENSTEDT, LARS, Dr. F. Hoffmann-La Roche Department of Psychiatry Grenzacherstr.124 Danderyd Hospital CH-4002 Basel S-182 88 Danderyd Switzerland Sweden

BR0SEN, KIM, Dr. BJORK, ANDERS, Dr. Dept. Clin. Pharmacology ABFerrosan Odense University P.O. Box 839 J.B. Winslews vej 19 S-20180Malmo DK-5000 Odense C Sweden Denmark

BoLWIG, TOM G., Dr. Psychiatric Department 0 CALIL, HELENA M., Dr. Depto. de Psicobiologia Rigshospitalet Blegdamsvej 9 Escola Paulista de Medicina Rua Botucatu, 862 -1 0 andar DK-2100 Copenhagen 0 04034 Sao Paulo Denmark Brazil

BOURIN, MICHEL, Dr. Pharmacologie Clinique CAMERON, ANNE, Dr. C.H.U. de Nantes Roche Norge AjS 1, Rue Gaston Veil P.O. Box41, Haugenstua F-44035 Nantes Cedex N-0915 Oslo 9 France Norway List of Participants 319

CASEY, DANIEL E., Dr. DOROW, RAINER, Dr. Psychiatric Service (116A) Schering AG Pharm. Research V.A. Medical Center Postfach 650 311 P.O. Box 1034 D-1000 Berlin (West) 65 Portland, OR 97207 FRG USA DOSE, MATHIAS, Dr. Max-Planck-Institut fUr Psychiatrie CHOPIN, PHILIP, Dr. 17 Avenue Jean Molin Kraepelinstrasse 10 Centre de Recherche Pierre Fabre D-8000 Munchen 40 F-8100 Castres FRG France DREYFUS, J.-F., Dr. J ouveinal Laboratoires CHRISTENSEN, ANNE V., Dr. 1, rue des Moissons Sct. Hans Hospital Sofilic423 Department E F -94 263 Fresnes Cedex DK-4000 Roskilde France Denmark EBERHARD, GORAN, Dr. DAHL, SVEIN G., Dr. Department of Psychiatry Instute of Medical Biology Malmo General Hospital University of TromS0 S-21401 Malmo P.O. Box 977 Sweden N-9001 Troms0 Norway EKDAL, PER, Dr. 9012 Asgard Psychiatric Hospital N-9001 Troms0 DAHL-PuuSTINEN, M.-L., Dr. Norway Department of Clinical Pharmacology EMRICH, H.M., Dr. Huddinge University Hospital Max-Planck- Institut fUr Psychiatrie S-141 86 Huddinge Kraepelinstrasse 10 Sweden D-8000 M unchen 40 FRG DELINI-STULA, ALEXANDRA, Dr. Ciba-Geigy Ltd. F ARDE, LARS, Dr. PH2.19 Department of Psychiatry Ch-4002 Basel Karolinska Hospital Switzerland S-10401 Stockholm Sweden DENCKER, SVEN J., Dr. KlinikII FOG, RASMUS, Dr. Lillhagen's Hospital Set. Hans Hospital Box 3005 Department E S-422 03 Hisings Backa DK-4000 Roskilde Sweden Denmark 320 List of Participants

GAII:'LOT, JEAN, Dr. HAFFNER, FRODE, Dr. Departement de Biodynamique Lier Psychiatric Hospital Institut de Biopharmacie N-1340Lier Rhone-Poulenc Sante Norway 20 Avenue Raymond Aron F-92160 Antony HALL, HAKAN, Dr. France Astra Research Centre SOdertillje, CNS Research and Development, GARVER, DAVID L., Dr. Neuropharmacology, CNS 2, Department of Psychiatry S-151 85 SOdertalje 231 Bethesda Avenue (ML 559) Sweden Cincinnati, OH 45267 USA HALS, PETTER-ARNT, Dr. Department of Pharmacology GENTIL, VALENTIM, Dr. NycomedAS Universidade De Sao Paulo P.O. Box 4220 Torshov Rua Oscar Freire, 587 N-0401 Oslo 4 01426 Sao Paulo Norway Brazil .

HEFFNER, THOMAS G., Dr. GEREBTZOFF, ALEXANDER, Dr. Department of Pharmacology Ciba-Geigy Ltd. Parke-Davis PH 2.19 Pharmaceutical Research CH-4002 Basel 2800 Plymouth Road Switzerland Ann Arbor, MI48105 GHANY, IGBAL M., Dr. USA St. Ann's Hospital 110 Frederick Street HENINGER, GEORGE R., Dr. Port-of-Spain Abraham Ribicoff Trinidad W.I. Research Facilities Spain Yale University 34 Park Street GRAM, LARS F., Dr. New Haven, CT 06508 Dept. Clin. Pharmacology USA Odense University J.B. Winsl0Ws vej 19 HENNING, MATTS, Dr. DK-5000 Odense C Ciba-Geigy Denmark P.O. Box 605 S-421 26 Vastra FrOlunda GREENWOOD, DAVID, Dr. Sweden Medical Research Dept. ICI Pharmaceuticals Div. HYTTEL, JOHN, Dr. Mereside Alderly Park H. Lundbeck AjS Macclesfield Ottiliavej 7-9 Cheshire SK10 4TG DK-2500Valby United Kingdom Denmark List of Participants 321

JOlINSEN, HELGE, Dr. LECRUBIER, YVES, Dr. Norwegian Defence Research Hopital de la Salpetriere Establishment Charge de Recherche INSERM Div. for Environmental 47, Bd de L'Hopital Toxicology F-Paris 75651 Cedex 13 P.O. Box 25 France N-7002 Kjeller Norway LIDEN, ANDERS, Dr. Dept. Psychiatry KALow, WERNER, Dr. and Neurochemistry Department of Pharmacology University of Lund Medical Sciences Building P.O. Box 638 University of Toronto S-220 06 Lund Toronto Sweden Canada M5S 1A8 LINDBERGET, JOSTEIN, Dr. KLEIN, MARCEL, Dr. OrganonAjS Institut R01,lssel Uclaf P.O. Box 325 102,111, Route de Noisy- B.P. 9 N-1372 Asker F-93 230 Romainville Norway France LINGJ..£RDE, ODD, Dr. KNORRING, LARS YON, Dr. Gaustad Psychiatric Hospital Departments of Psychiatry P.O. Box 24 Gaustad University ofUmea N-0320 Oslo 3 S-90 185Umea Norway Sweden LINK, e.G.G., Dr. KNORRING, ANNE-LIS YON, Dr. Beecham Pharmaceuticals Department of Child and Youth Medicinal Research Centre Psychiatry Coldharbour Road University ofUmea The Pinnacles S-90 185Umea Harlow, Essex CM19 5AD Sweden United Kingdom

KOSSMANN, LoUIS, Dr. LoVENBERG, WALTER, Dr. Laboratoires Delagrange Merrell Dow Research Institute 1, avenue Pierre Brossolette Strasbourg Research Center F-91380 Chilly-Mazarin 16, rue d' Ankara France F-67084 Strasbourg Cedex France LAYOISY, J., Dr. Laboratoires ICI-Pharma LUND, J0RGEN, Dr. 1, rue des Chauffours Ferrosan Group B.P.127 Sydmarken5 F-95022 Cergy Cedex DK-2860 Seborg France Denmark 322 List of Participants

MELTZER, HERBERT Y., Dr. NELSON, J. CRAIG, Dr. Department of Psychiatry Department of Psychiatry Case Western Reserve University Yale Univ. School of Medicine School of Medicine 333 Cedar Street 2040 Abington Road New Haven, CT 06504 Cleveland, OH 44106 USA USA NILSEN, CLAES, Dr. MARDER, STEVEN R., Dr. Eli-Lilly West L.A. VA Medical Center Temmerup Stationsvej 10 Brentwood Division DK-2770 Kastrup 11301 Wilshire Blvd. Denmark Los Angeles, CA 90073 USA NILSSON, HEIMo L., Dr. Ciba-Geigy MESTIKAWY, S. EL, Dr. Box 605 INSERMU288 S-421 26 Vastra Frolunda 91 Boulevard de I' Hopital Sweden F-75 634 Paris Cedex 13 France NYBERG, GOSTA, Dr. Department III MEYER, URs,Dr. Lillhagen Hospital Department of Pharmacology S-422 03 Hisings Backa Biocenter Sweden University of Basel CH-4056 Basel POLLOCK, BRUCE G., Dr. Switzerland Department of Psychiatry University of Pittsburgh MONTGOMERY, STUART A., Dr. School of Medicine Academic Dept. of Psychiatry Western Psychiatric St. Mary's Hospital Institute and Clinic Praed Street 3811 O'Hara Street London W2 1NY Pittsburgh, PA 15213 United Kingdom USA

MUSCH, BRUNO, Dr. POTTER, WILLIAM Z., Dr. CNS Clinical Research Clinical Psychobiology Branch Rhone-Poulenc Sante NIMH, Building 10 Room 2D46 20, Avenue Raymond Cedex 9000 Rockville Pike F-92165 Antony Cedex Bethesda, MD 20892 France USA

MARTENSSON, ERIK, Dr. POURRIAS, B., Dr. Psychiatric Department III Centre de Recherche Delalande Lillhagen's Hospital 10, rue des Carriers S-42203 Hisings Backa 3 F-92 500 Rueil-Malmaison Sweden France List of Participants 323

PRESKORN, SHELDON H., Dr. SCHWARTZ, J.C., Dr. Department of Psychiatry 452/116 Unite de Neurobiologie University of Kansas Centre Paul Broca de l' INSERM School of Medicine-Wichita 2 ter, Rue d' Alesia 1010N. Kansas F-75014 Paris Wichita, KS 67214 France USA SIEGHART, WERNER, Dr. Psychiatrische Universitatsklinik PuECH, ALAIN, Dr. Departement de WahringerGiirtel18-20 Pharmacologie Clinique A-1090Wien Groupe Hospitalier Pitie-Salpetriere Austria 47, Boulevard de l'Hopital F-75651 ParisCedex 13 SIMON, PIERRE, Dr. France Societe Sanofi Recherche 37 Avenue Pierre 1 er de Serbie F-75008 Paris RmSBY, NIL'S, Dr. France Arhus Psychiatric Hospital DK-8240 Risskov SITSEN, J.M.A., Dr. Denmark Scientific Development Group Organon International BV RmTEN, AsLAUG, Dr. P.O. Box 20 Upjohn Informasjon NL-5340 BH Oss Postboks 6749 St. Olavs plass The Netherlands N-0130 Oslo 1 Norway SJOQVIST, FOLKE, Dr. Department of Clinical RUTZ, WOLFGANG, Dr. Pharmacology Norrahansegatan 4 Huddinge University Hospital S-621 00 Visby S-14186 Huddinge Sweden Sweden

SPINA, EDOARDO, Dr. SAGER, GEORG, Dr. Institute of Pharmacology Institute of Medical Biology University of Messina University of Troms0 Piazza XX Settembre, 4 P.O. Box 977 1-98100 Messina N-9001 Troms0 Italy Norway TEIGEN, LISE, Dr. SCHUSTER, MARTIN, Dr. Sentipharm AG 9010 Asgard Psychiatric Hospital Aslakveien 14 N-9001 Troms0 N-0753 Oslo 7 Norway Norway 324 List of Participants

THmKOTTER, THOMAS, Dr. WAKELIN,J.S., Dr. Springer-Verlag Duphar Postfach 10 52 80 Clinical Research Department D-6900 Heidelberg 1 P.O. Box 900 FRG NL-1380DA Weesp The Netherlands

VESTERGAARD, PER, Dr. WIESEL, FRITS-AxEL, Dr. Arhus Psychiatric Hospital Department of DK-8240 Risskov Psychiatry and Psychology Denmark Karolinska Hospital S-10401 Stockholm VON BAHR, CHRISTER, Dr. Sweden Department of Clinical WIK, GUSTAV, Dr. Pharmacology 9012 Asgard Psychiatric Hospital Astra Research Centre N-9001 Tromsl2J S-151 85 SOdertiilje Norway Sweden WILLIAMS, D. CLIVE, Dr. WAHLEN, ANITA, Dr. Dept. of Biochemistry Astra Alab AB Trinity College S-151 85 SOdertaIje Dublin 2 Sweden Ireland Subject Index

Page numbers given are the first pages of chapters in which the subject listed is discussed

abberant pre-mRNA 141 arrhythmias 232,237 acetylcholine receptors, muscarinic 3, 52, asternizole 10 109 ataxia 237 active metabolites, neuroleptics 244,257 atypical 105 adenylate cyclase 3,109,123 autoinhibiton of release 10 dopamine stimulated 3 adenylate cyclase coupling 10 barbiturates 219 adrenergic receptors, IX- 109 behavioural despair 285 adrenergic receptors, IX 1-' 3 behavioural models 285 adrenergic reCeptors, IXz- 3 109 adrenergic receptors, fJ- 3 benzodiazepine binding sites, adrenoceptor agonists, IX2- 285 peripheral 131 adrenoceptor antagonists, IX 2- 40, 105 benzodiazepine receptor agonists 131 adrenoceptor antagonists, fJ- 141 benzodiazepine receptor antagonists 131 adrenoceptors, presynaptic IX 2- 105 imidazobenzodiazepine 131 adverse drug reactions 219,232,237,311 pyrazolopyridazines 131 age 228 benzodiazepine receptor types (1,2) 131 agranulocytosis 311 benzodiazepine receptors 20,131 ajmaline 148 benzodiazepines 109,131,148,296 akathisia 269 blood-brain barrier 52 akinesia 269 blood pressure 232,257 consumption 228 bradycardia 232 alprazolam 296 brain damage 68 amine metabolites 296 brofaromine 285 40,52,60,81,105,172,181, bromazepam 131 192,206,219,237,285 bromospiperone 20 68 bufaralol 141,148,211 amphetamine 109 bulbocapine 3 anergia 68 285 anhedonia 68 burimanide 10 antiarrhythmics 141 94 anticholinergic effects 52 butaclamol 3 anticonvulsant effect 131 244 activity 285 20,68,109 antidepressant drug treatment 52, 285 antidepressants 105, 163, 172, 192,211, Ca 2+ channels 131 285,296 Ca2+ mobilization 10 antipyrine 172 carbolines,fJ- 3,131 antistereotypic activity 109 cardiac conductance 219,237,257 anxiety 94 cardiac contractility 232 anxiogenic effect 131 cardiac function 257 anxiolytic effect 131 cardiac output 232 anxiolytics 109,123,285,296 cardiotoxicity 232 arousal control 10 carfentalyl 20 326 Subject Index catalepsy 123,285 DNA-cDNA 141 cataleptogenic activity 109 dopamine 40,94,109 cerebrospinal fluid (CSF) 40 dopamine receptor agonists, D1 3,109 chloride ion channel 131 dopamine receptor antagonists 123,296 chlorogyline 40 dopamine receptors, D1 3,20,109,123 chlorophenylpiperazine, m- (MCPP) 94 subtypes 3 3,20,40,68,109,163, dopamine receptors, D2 3,20,32,109, 206,244,257 123,244,257,263,303 chromosome 22,141 striatum 20 10, 172, 181 dopamine release, nucleus accumbens 40 cinolazepam 131 dopamine reuptake inhibition 296 cinopramine 285 dopamine turnover, striatum 123 cis(Z)- 109 dose dependent kinetics 172,181,192,211 cis(Z)-flupenthixol 109 dose finding 32, 303 citalopram 40,81,285 dose response relationship 303 C1218872 131 doxepine 237,285 clinical trials 81, 109 drug concentrations, brain 32 40,81,211,228,285 drug concentrations, cerebrospinal clonazepam 141 fluid 52,244,257 cloning of receptors 3 drug concentrations, erythrocytes 244 clothiapine 3,109,206 drug concentrations, free unbound 244 . 3,68,109,206,311 drug concentrations, plasma/serum 32, CNS toxicity 237 219,257,280,303 codeine 141,148 drug development 211 demethylation 148 drug interactions 163,172,219 cognitive disturbances 68 drug level monitoring 192,228,237,257, compliance 280 269,280 computer graphics 60 drug metabolism 141,163,172,181,192, convulsant effect 131 219,257 cortison secretion 94 in brain 148 coupling states 3 drug oxidation 141,148,201,211 CSF /plasma concentration ratio 232 drug protein binding 257 cyclic AMP 3,10 drug receptors 3 cyclic GMP 10 drug toxicity 219,232,237,280 cytochrome P450 52,141,148,163,172, DSM-III 263 181,192,201,211 purified isozymes 163 EEG 296 enantiomers 148 debrisoqine 141,148,163,172,181,192, endogenous ligand 3 201,206,211 ethnic variation 141 delirium 237 ethytoin 148 delusions 68 excitatory amino acid receptors 3 demethylation 163,172,228 extensivemetabolizers(EM) 141,172,192, depot neuroleptics 269 206 depression rating 81 extrapyramidal effects 3, 32 40,94,163,172,181,192, extrapyramidal symptoms 20,263,269, 201,206,219,237,285 280 desmethylclomipramine 211,228 desmethylmetabolites, neuroleptics 257 family studies 181,192 dextromethorphan 141,192 fear-anxiety like behaviour 94 diacylglycerol 10 flattened affect 68 diastereoisomers 52 flunitrazepam 131,296 diazepam 109, 131, 148 81,285 dibenzepine 3 flupenthixol 3 diltiazem 148 flupenthixol decanoate 109 10 3,109 Subject Index 327 109,206,244,269 histamine receptors, H3 10 fluphenazine decanoate 109 decarboxylase, L- 10 fluphenazine sulphoxide 269 homovanillic acid (HMA) 140 fluvoxarrrine 81,94,285 hormone receptors 3 human liver 163,201,211 Gprotein 3 human liver bank 141,163 GABA, benzodiazepine receptor complex, IX hydroxydesipramine, 2- 109, 201, 232 and p subunits 131 hydroxy-DPAT,8- 94 GABA receptors 3 hydroxyhaloperidol (reduced gamma-aminobutyric acid (GABA) 10,131 ) 263 gamma butyrolactone 123 hydroxyidolacetic acid, 5- (5HIAA) 40 gene abnormalities 141 hydroxyimipramine,2- 232 defective transcription 141 hydroxylation 163,172,181,201,228 deletion 141 hydroxymetabolites 52,60,219,228,232,257 insertion 141 hydroxynortriptyIine, E-l0 52, 60, 232 rearrangement 141 hydroxynortriptyIine, Z-10 52, 60, 232 gene expression 141 hyperactivity 123 genetic polymorphism 141,148,181,192, hypothalamus, posterior 10 201,206,211,228 hypothermia 285 94 glucoronide metabolite formation 52 idazoxan 40,105,285 glutathione-S"transferase 163 ifoxetine 285 GR431175 94 imidazobenzodiazepine 131 growth hormone secretion 94 40,60,81,163,172,181,192, GTP regulatoring proteine 3 206,219,232,237,285 immune receptors 3 hallucinations 68 immunoquantitation 141 haloperidol 68,109,123,163,192,206, in vito inhibitors 172 244,263 in vitro drug metabolism 163,181,211 head-twitch 109 inhibition of 163 healthy volunteers 52,296 induction of drug oxidation 148 hepatic blood flow 148 inhibition of drug metabolism 219 hexobarbital 148 inhibitors of drug oxidation 148, 201,206,211 high affinity binding sites 131 inhibitory transmitters 131 agonists, H2 10 inositol phosphate 10 dimaprit 10 inositol phospholipids 10 ipromidine 10 intestinal glucuronidation 52 histamine receptor agonists, H3 10 inverse benzodiazepine receptor R-IX-methylhistamine 10 agonists 131 histamine receptor antagonists 10 ion channel gating receptor 3 histamine receptor antagonists, H 1 10 ipronidine 10 asternizole 10 isapirone 94 mezuitazine 10 isoniazide 141 10 isozymes, cytochrome P450 141,148,163, histamine receptor antagonists, H2 10 172,181,192 cimetidine 10 jamotidine 10 jamotidine 10 10 tiotidine 10 ketansenin 3,109 histamine receptor antagonists, H2/H3 10 burimanide 10 L- 10 histamine receptor antagonists, H3 10 l- 3 10 learned helplessness 296 histamine receptors 10, 109 172, 206, 296 histamine receptors, H 1 10 levoprotiline 285 histamine receptors, H2 10 lithium 94 328 Subject Index

liver metabolism 52,141,148,163 nonspecific antibodies against drug oxidiz• liver microsomes 52 ing isozymes 163 noradrenaline 40,52,123,131 4M 09151-2 109 reuptake 40 maintenance therapy 269 reuptake inhibition 296 MAO inhibitors 94,285,296 normetanephrine 40 285, 296 40,52,60,163,172,181,192, MD 780236 285 206,219,232,285 68 memory 296 obligate heterozygotes 141 memory enhancing 131 obsessive compulsive disease 94 mephenytoin 141,148,172 octoclothepin 109 mephobarbital 148 oligonucleotide probes 163 94, 109 opiate receptors (J.1) 20 meta-analysis 81 285 metabolic ratio 192,206 panic disorder 94 94 parachlorophenylamine (PCPA) 94 methiothepin 109 paralytic ileus 237 methosuximide 148 Parkinson's disease 109,141 3-methoxy-4-hydroxyphenylglycol 109 (MHPG) 40 pericyazine 206 methyl-br~mo-LSD 20 109 methylphenidate 109 109,163,219,280 metoprolol 181 pharmacokineticvariability 141,163,181, mezuitazine 10 192,211,219,228,244,257,263,280 105,109,285 phenelzine 141 micotinic receptor 3 20,68,109,228,257 microsomal drug oxidation 141,148,163, phenotype 141,172,181,192,206,211 211 pifluthixol 109 microsomes 201 plasma level-effect relationship 263 molecular dynamics 60 plasma protein binding 32,244, 257 molecular electrostatic potentials 60 platelets (thrombocytes) 40 molecular graphics 60 poor metabolizers (PM) 141,172, 192,206,237 molecular mechanics 60 population studies 181,192 molecular modelling 60 positive symptoms, 68 molecular structure, three dimensional 60 positron emission tomography (PET) 20, 3 32,296 monoamine oxidase inhibitors 40 post marketing surveillance 311 monogenetic inheritance 141 PR interval 232 morphine 148 preclinical evaluation 285 muscarinic acetylcholine receptor 52, 109 probenecid 40 muscimol 131 procainamide 148 muscle relaxant effect 131 20 mutated alleles 141 prolactin secretion, induced 94 propafenone 148 N-acetyltransferase 141 proteine kinase C activator 10 NB 106-094 3 psychosocial intervention 68 negative symptoms, schizophrenia 68 pyrazolopyridazines 131 N-ethoxycarbonyl-2-ethoxy-l,2- dihydroquinoline (EEDQ) 3 QRS interval 232 neuroendocrine response 296 quantum mechanics 60 neuroleptics 163,172,192,219,237,244, quazepam 131 257,263,269,280,296,303 quinidine 148,163,172,201,211,219 neurotransmitter interactions 40 quinpirole 109 neurotransmitters 3 109 nomifensin 285,311 quisqualate 3 Subject Index 329

R-IX-meiliylhistamine 10 20,109 raclopride 20,32,109,123 [3H]spiperone 123 radioimmuno assy 244 spiroperidol 3 radiolabelled ligands 20, 32 splicing defects 141 radioreceptor assay 244,257 stereoselectivity 141,148 ranitidine 10 stereotypies 123 raphe nucleus 40 stress tests 296 receptor antagonists 109 striatum/cerebellum receptor ratio 20 receptor binding 296 substania nigra 40 receptor occupancy 20, 32 sudden death 237 receptor selectivity 3,10 sulfamethazine 141 receptor supersensitivity 109 sulphoxide metabolites 257,269 receptor up-regulation 20 sulpiride 123,206, 303 123 sulpiride, 1- 3 285 restriction fraction length polymor• tardive dyskinesia 3, 109 phism 141 taste receptors 3 retardation 68 tefludazine 109 reuptake inhibition 52, 285 tefluthixol 109 noradrenaline 52,285 terfenadine 10 serotonine 52,285, 296 285 ri tanserin 94, 109 thioperamide 10 RNA 141 206 Ro 5-4864 131 123,163,172,181,206,244, rolipram 285 257 RU24213 109 thiothixene 244 68,109 salivation 52 thought disorder 68 SCH 15225 131 threshold receptor occupancy 32 SCH 23390 3,109 tiotidine 10 schizophrenia 3,20,32,68,263,269 toxin receptors 3 scopolamine 109 tranylcypromine 94,148 sedative effect 131, 296 94,285 seizures 237 tremor 237 selective reuptake inhibitors 40 triazolam 296 selectivity of inhibitors 172 triazolopyridazine 131 serotonin (5-HT) 40,52,81,123,285 antidepressants 40,60,81,105, serotonin antagonists, S2 94 141,228,232,237 serotonin receptors 94, 109, 131 trifluperazine 206 agonists 94 285,296 antagonists, unspecific 94 tryptophan 94 subtypes 94 tryptophan depletion 296 serotonin receptors, S2 20,109 tubero-mammilary nucleus 10 serotonin reuptake 40, 81,296 twin studies 181 inhibition 52,285,296 inhibitors 81 ultrafiltration 32 setoperone 20,68,109 uptake receptors 3 side effects 81,163,219,269,280 vanillylmandelic acid (VMA) 40 SKF 38393 109 vigilance 131 SKF 83566 109 285 sleep deprivation 296 sleep disturbancy 81 X-ray crystallography 60 slow hydroxylators 201 smoking of tobacco 228 zimelidine 40,285 sparteine 141,148,163,172,181,192,201, zopiclone 296 206,211 109